Qiagen NV (QGEN) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Qiagen NV (NYSE:QGEN) have been assigned an average recommendation of “Hold” from the fifteen brokerages that are presently covering the company, MarketBeat reports. Eight research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $40.00.

QGEN has been the subject of several research analyst reports. UBS Group initiated coverage on Qiagen in a research note on Friday, March 15th. They issued a “neutral” rating and a $42.00 price objective for the company. Deutsche Bank reissued a “buy” rating on shares of Qiagen in a research note on Tuesday, January 29th. Finally, Jefferies Financial Group reissued a “neutral” rating on shares of Qiagen in a research note on Monday, January 21st.

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc raised its stake in shares of Qiagen by 2.0% during the 3rd quarter. Vanguard Group Inc now owns 6,627,163 shares of the company’s stock worth $251,037,000 after purchasing an additional 128,125 shares in the last quarter. Morgan Stanley raised its stake in shares of Qiagen by 16.3% during the 3rd quarter. Morgan Stanley now owns 1,468,052 shares of the company’s stock worth $55,611,000 after purchasing an additional 205,698 shares in the last quarter. State of Alaska Department of Revenue raised its stake in shares of Qiagen by 2.0% during the 4th quarter. State of Alaska Department of Revenue now owns 23,547 shares of the company’s stock worth $811,000 after purchasing an additional 463 shares in the last quarter. Quadrant Capital Group LLC raised its stake in shares of Qiagen by 104.5% during the 4th quarter. Quadrant Capital Group LLC now owns 6,923 shares of the company’s stock worth $229,000 after purchasing an additional 3,538 shares in the last quarter. Finally, Advisors Capital Management LLC purchased a new stake in shares of Qiagen during the 4th quarter worth about $272,000. 64.77% of the stock is owned by hedge funds and other institutional investors.

Shares of NYSE:QGEN traded up $0.42 during midday trading on Monday, reaching $40.68. The company had a trading volume of 561,102 shares, compared to its average volume of 1,231,341. The company has a quick ratio of 2.05, a current ratio of 2.22 and a debt-to-equity ratio of 0.63. Qiagen has a 1-year low of $31.10 and a 1-year high of $40.76. The firm has a market capitalization of $9.17 billion, a price-to-earnings ratio of 30.36, a price-to-earnings-growth ratio of 2.28 and a beta of 0.91.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Monday, February 4th. The company reported $0.40 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.40. Qiagen had a return on equity of 12.15% and a net margin of 12.68%. The business had revenue of $403.20 million during the quarter, compared to analyst estimates of $409.32 million. During the same quarter last year, the company posted $0.43 EPS. Qiagen’s revenue for the quarter was up 1.6% on a year-over-year basis. Equities analysts predict that Qiagen will post 1.45 earnings per share for the current year.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Featured Story: Capital Gains

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.